Molecular Diagnostics

1957–1988 · 1 of 6

Hybridization and Amplification Diagnostics

1957–1988

Hybridization and Amplification Diagnostics

Contemporary themes

Sequence-specific detection by membrane-filter hybridization and DNA probes defined a new diagnostic standard, enabling targeted screening across clinical samples. At the same time, enzymatic amplification of DNA broadened capabilities to rapid disease detection and prenatal testing, while allele-specific and polymorphism-based analyses advanced carrier screening and risk assessment. Prenatal screening and mutation-focused diagnostics began to shape personalized risk profiling by integrating molecular markers with traditional testing.

  • Hybridization-based detection using DNA probes emerged as a core diagnostic paradigm, enabling sequence-specific screening across the late 1960s–1980s via membrane-filter assays, oligonucleotide probes, and DNA hybridization methods.
  • Amplification-based diagnostics expanded capacity for direct disease detection and prenatal testing through enzymatic amplification, amplified DNA analyses, and HIV-1 DNA amplification from 1985–1988.
  • Prenatal diagnosis and genetic screening advanced through endonuclease mapping and analyses of linked DNA polymorphisms, enabling antenatal risk assessment and detection based on gene-linked markers.
  • Allele-specific diagnostics and mutation-focused analyses for sickle cell and related β-globin disorders used targeted probes, amplification, and mutation detection to characterize diagnostic variants.

Influential works

The period established foundational paradigms that persisted and expanded in later decades, with hybridization-based detection and DNA amplification maturing into routine, scalable diagnostics. These innovations laid the groundwork for polymerase chain reaction-driven diagnostics and modern genomic screening, enabling faster, more sensitive tests across medicine and public health.

  • A membrane-filter technique for the detection of complementary DNA (1966) introduced a membrane-filter hybridization approach to detect complementary DNA, enabling sequence-specific detection on filters and laying the groundwork for blotting methods central to molecular diagnostics.
  • Detection of specific sequences among DNA fragments separated by gel electrophoresis (1975) formalized the Southern blot concept, transferring DNA to membranes and probing for specific sequences, fueling genetic testing and disease diagnosis.
  • Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I (1977) provided nick translation labeling to create highly active DNA probes, boosting hybridization sensitivity for diagnostics.
  • Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia (1985) demonstrated polymerase chain reaction (PCR), enabling exponential DNA amplification for rapid genetic testing and catalyzing the modern diagnostic revolution.
  • A simple technique for quantitation of low levels of DNA damage in individual cells (1988) introduced the Comet assay, a versatile single-cell gel electrophoresis method now standard in genotoxicity testing and cancer research.

1989–1995

Polymerase Chain Reaction Diagnostics

Contemporary themes

During 1989–1995, Polymerase Chain Reaction became the core tool of molecular diagnostics, enabling rapid, sensitive detection of pathogens and human genetic variants across diverse specimen types and clinical contexts. Mutation-detection methods expanded beyond sequencing to include Amplification-Refractory Mutation System (ARMS), Single-Strand Conformation Polymorphism (SSCP), Denaturing Gradient Gel Electrophoresis (DGGE), and immobilized-probe strategies, enabling rapid, scalable screening. Broad-spectrum pathogen detection and general-primer PCR approaches supported investigations across viruses, bacteria, and fungi, and underpinned cancer diagnostics by enabling mutation monitoring and molecular characterization.

  • Polymerase chain reaction (PCR) emerged as the core tool for molecular diagnostics, enabling rapid, sensitive detection of pathogens and human genetic variants across diverse specimen types and clinical contexts.
  • Genetic analysis of disease genes and genotype–phenotype mapping were advanced by identifying the CFTR gene and key mutations (e.g., ΔF508) to relate genotypes to CF expression.
  • Mutation-detection methodologies evolved beyond sequencing via amplification-based and non-radioactive strategies—ARMS, SSCP, DGGE, and immobilized probes enabling rapid screening.
  • Cancer-focused molecular diagnostics leveraged PCR/SSCP to detect tumor-associated mutations and monitor disease, including p53 mutations in brain tumors and circulating tumor cells in blood.
  • Broad-spectrum pathogen detection and general-primer strategies enabled questioning across viruses, bacteria and fungi, exemplified by HPV general primers and broad PCR-based pathogen assays.

Influential works

  • Identification of the Cystic Fibrosis Gene: Genetic Analysis — this paper identified the CFTR gene, enabling targeted carrier screening, prenatal diagnosis, and disease-specific testing; it anchored molecular diagnostics for inherited disorders and catalyzed gene-based testing approaches.
  • Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction — introduced Polymerase Chain Reaction (PCR) as a rapid, sensitive assay for detecting point mutations and polymorphisms, transforming diagnostic genetics and enabling scalable mutation screening across inherited diseases and cancer.
  • Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase — defined a real-time polymerase chain reaction (PCR) detection approach by exploiting the 5'→3' exonuclease activity, enabling quantitative monitoring of amplification for rapid clinical diagnostics.
  • PCR-SSCP (polymerase chain reaction-single-strand conformation polymorphism) — offered a simple, highly sensitive mutation screen by observing conformational shifts in single-stranded DNA after PCR, accelerating gene discovery and diagnostics.
  • Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing — PFGE-based criteria revolutionized bacterial typing, enabling high-resolution outbreak investigations and clinical microbiology epidemiology.

1996–2006

Gene Expression Diagnostics: Microarrays

Contemporary themes

Real-time quantitative polymerase chain reaction and high-density oligonucleotide arrays empowered accurate, scalable molecular profiling of cancer, enabling signatures that classify tumors and predict outcomes across lung, breast, melanoma, and leukemia. Epigenetic methylation patterns such as p16INK4a and APC promoter methylation, along with serum DNA patterns, emerged as early disease indicators and prognostic tools. Advancements in diagnostic technologies, including real-time PCR and high-density array platforms, facilitated translation of molecular profiling into routine clinical practice, supported by robust data normalization and summarization methods. Computational learning approaches for gene-expression data aided class discovery, subtype delineation, and outcome prediction, driving a shift toward data-driven, personalized diagnostics.

  • Gene expression profiling enables cancer classification and prognosis via signatures across lung, breast, melanoma, and leukemia, reflecting widespread utility. Notable demonstrations span molecular cancer classification and patient outcomes in several tissues.
  • Epigenetic methylation patterns (p16INK4a, APC promoter, serum DNA) serve as early/disease markers and prognostic indicators.
  • Advances in diagnostics technology, including real-time PCR and high-density oligonucleotide arrays, enable scalable molecular profiling for clinical use.
  • Computational learning from gene-expression data supports class discovery, subtype identification, and outcome prediction.

Influential works

The convergence of quantitative expression measurement, large-scale profiling, and epigenetic marker discovery established a foundational paradigm that molecular signatures can inform prognosis and guide therapy. The period produced pivotal frameworks for class discovery and class prediction by gene-expression monitoring, influencing subsequent generations of cancer diagnostics and personalized medicine. Early adoption of epigenetic patterns as biomarkers and the maturation of analytical pipelines for microarray data created enduring infrastructure for biomarker discovery and diagnostic assay development that shaped the field for years to come.

  • Real time quantitative PCR (1996) introduced real-time monitoring of PCR amplification, enabling precise, quantitative measurement of nucleic acids without end-point analysis, catalyzing rapid clinical diagnostics and gene-expression studies; a foundational tool in molecular diagnostics.
  • Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring (1999) proposed using gene-expression profiling to classify cancers and discover molecular classes, enabling class discovery and prediction and laying the groundwork for molecular diagnostics and personalized oncology.
  • Gene expression profiling predicts clinical outcome of breast cancer (2002) demonstrated that genome-wide expression patterns can predict outcome, providing prognostic value beyond histology and driving development of expression-based signatures for personalized treatment.
  • Exploration, normalization, and summaries of high density oligonucleotide array probe level data (2003) provided robust methods for normalization and summarization of microarray data, addressing variability and comparability and becoming foundational for diagnostic biomarker discovery.
  • Mfold web server for nucleic acid folding and hybridization prediction (2003) introduced an accessible web-based tool for folding and duplex predictions, guiding primer/probe design and in silico validation, accelerating diagnostics assay development.

2007–2013

Circulating microRNA Diagnostics

Contemporary themes

Circulating microRNAs in serum, plasma, and exosomes emerged as a robust, noninvasive biomarker class with potential for early cancer detection; cross-cancer stability and diagnostic promise were demonstrated across breast, colorectal, ovarian, and lung cancers. Advances in detection platforms and microRNA extraction techniques underpinned reliable measurement and cross-study comparability, enabling progress toward clinical translation in routine diagnostics. Expression patterns showed tissue-specific signatures that could differentiate cancer type and prognosis, supporting diagnostic and prognostic utility, while complementary computational analyses and high-throughput mutation frameworks began to contextualize microRNA findings within the broader biomarker discovery paradigm.

  • Circulating microRNAs in serum, plasma, and exosomes are consistently proposed as noninvasive biomarkers for early cancer detection, with cross-cancer stability and diagnostic potential demonstrated by multiple studies across breast, colorectal, ovarian, and lung cancer.
  • Advances in detection platforms (qRT-PCR, real-time PCR) and microvesicle/serum microRNA extraction underpin reliable measurement of circulating miRNAs in clinical contexts, with methodological reports illustrating differential expression assessment and cross-study comparability.
  • MicroRNA expression patterns enable cancer-type and prognostic differentiation, showing tissue-specific signatures that distinguish breast, colorectal, ovarian, and lymphoma contexts, thereby supporting diagnostic and prognostic biomarker utility.
  • Complementary computational and high-throughput mutation analyses frame molecular diagnostics within a broader biomarker-discovery paradigm, including functional impact prediction and large-scale oncogene profiling to contextualize miRNA findings.

Influential works

The period catalyzed the birth of the liquid biopsy concept by establishing circulating microRNA biomarkers as stable, disease-associated indicators in blood, with broad implications for noninvasive screening and monitoring in oncology. Foundational characterizations identified serum microRNAs as disease- and tissue-specific biomarkers, laying a framework for noninvasive diagnostics and prognostics in clinical practice. At the same time, the integration of computational tools for mutation interpretation and predictive analyses anticipated the future convergence of molecular diagnostics with genomic data, signaling a paradigm shift toward precision medicine.

  • The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) provides biomarker-supported criteria that integrate clinical features with imaging and CSF biomarkers to stage disease and standardize diagnosis across research and clinical practice, catalyzing both early detection and consistent trial inclusion.
  • Circulating microRNAs as stable blood-based markers for cancer detection demonstrates that microRNAs circulating in blood are remarkably stable and disease-associated, enabling noninvasive cancer detection and launching the modern field of liquid biopsy with broad implications for screening and monitoring in oncology.
  • Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases identifies serum miRNAs as disease- and tissue-specific biomarkers, providing a foundational framework for noninvasive cancer diagnostics and prognosis in clinical practice.
  • A method and server for predicting damaging missense mutations (PolyPhen-2) introduces a unified framework combining sequence conservation, structural context, and machine-learning insights to predict deleterious amino acid substitutions, greatly enhancing variant interpretation in genetic diagnostics.
  • A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff automates rapid, scalable annotation of SNP impacts on genes and transcripts, enabling efficient integration into diagnostic sequencing pipelines and large-scale mutation interpretation.

2014–2017

Liquid Biopsy Driven Profiling

Contemporary themes

Noninvasive molecular diagnostics increasingly relied on circulating nucleic acids, including cell-free DNA and exosomal DNA, to detect mutations and monitor treatment response across cancer types. Standardization efforts yielded guidelines for interpreting variants and validating targeted capture methods, accelerating clinical translation of sequencing-based tests. Broad tumor profiling across cancers identified driver alterations and actionable targets, fueling precision oncology and informing targeted therapies, while early signals from noncoding RNA biomarkers and exosome-based sensing expanded the liquid biopsy toolbox.

  • Noninvasive molecular diagnostics across cancer types rely on circulating nucleic acids (cfDNA/plasma DNA/exosomal DNA) to detect mutations, monitor treatment response, and track resistance, as demonstrated by cfDNA-based EGFR resistance monitoring, deep sequencing of circulating DNA in lung cancer, and exosome-associated DNA biomarkers.
  • Standardization and clinical translation of sequencing-based diagnostics emphasize guidelines for interpreting variants, validation of targeted capture methods, and policy guidance to integrate in practice.
  • Comprehensive tumor molecular profiling across cancers identifies driver alterations and actionable targets enabling precision oncology, with lung adenocarcinoma and gastric cancer profiling providing broad mutational landscapes.
  • Noncoding RNA and circular RNA biomarkers offer promising blood-based signals for early detection, including circulating microRNAs and stable exosomal circRNAs; multiple studies establish their diagnostic potential.
  • Exosome-based sensing and molecular profiling technologies enable label-free exosome profiling and nanosensor-based detection, expanding liquid biopsy capabilities.

Influential works

The period solidified a paradigm shift toward standardized interpretation of sequencing results and routine use of comprehensive tumor profiling panels, setting the stage for precision oncology. Advancement of rapid, targeted sequencing panels enabling actionable mutation–therapy links reshaped clinical workflows and surveillance for resistance and disease progression. Foundational analytic resources and pathway-oriented gene sets standardized enrichment analyses, accelerating biomarker discovery and cross-study comparability.

  • Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (2015) established a widely adopted five-tier variant classification framework, transforming diagnostic reporting and cross-lab consistency in clinical genomics.
  • Comprehensive molecular profiling of lung adenocarcinoma (2014) provided integrated, multi-omic characterization of LUAD, revealing driver mutations, mutational landscape, and subtypes that underpin modern diagnostic panels and targeted therapies in lung cancer.
  • Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) (2015) introduced a comprehensive tumor sequencing panel linking somatic mutations to actionable therapies, catalyzing routine clinical tumor profiling and precision oncology practice.
  • Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications (2015) proposed an efficient SV/indel detection approach, enabling improved diagnostic interpretation of structural variation in clinical sequencing pipelines.
  • The Molecular Signatures Database Hallmark Gene Set Collection (2015) curated robust, interpretable gene sets that standardize enrichment analyses, accelerating translational oncology research and biomarker discovery.

2018–2024

Genomic and Liquid-Biopsy Diagnostics

Contemporary themes

The period is defined by rapid advancement and deployment of molecular diagnostics that span infectious disease and cancer. Rapid molecular assays for viruses, exemplified by field-ready isothermal amplification and colorimetric readouts, complemented by CRISPR-based detection to enable point-of-care testing. Simultaneously, integrated testing approaches combine nucleic acid assays with serology to map infection windows and guide clinical decisions, while liquid-biopsy centric methods leveraging cell-free DNA methylation, genome-wide methylation profiles, and exosomal biomarkers push noninvasive cancer detection and classification. In parallel, biomarker-guided therapy decisions—such as microsatellite instability status, tumor mutational burden, and targeted molecular panels—solidified genomics as the central pillar of precision oncology.

  • Rapid molecular diagnostics for SARS-CoV-2 dominated early 2020, emphasizing isothermal amplification (RT-LAMP) with colorimetric/visual readouts and complementary CRISPR-based detection to enable field-deployable testing.
  • Integrated COVID-19 testing approaches combining nucleic acid assays with serology and humoral profiling to capture infection status across windows and inform clinical decisions.
  • Liquid-biopsy-centric cancer detection leveraging cfDNA methylomes, genome-wide methylation and exosomal biomarkers to enable non-invasive early cancer detection and classification.
  • Biomarker-driven cancer prognosis and therapy decisions, guided by MSI status via NGS, tumor mutational burden, and guideline-based molecular testing for targeted therapies.

Influential works

  • "Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR" (2020) Introduced the first validated real-time RT-PCR assay for SARS-CoV-2, enabling rapid, scalable diagnostics and outbreak surveillance; established design principles and performance benchmarks that underpinned millions of tests and subsequent assay development.
  • "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2" (2020) Solved the molecular structure of SARS‑CoV‑2 spike protein binding to ACE2, revealing receptor engagement mechanics and guiding vaccine design, neutralizing antibodies, and entry inhibitors; foundational for understanding infectivity and therapeutic targeting.
  • "Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review" (2018) Comprehensively evaluated ctDNA as a noninvasive cancer biomarker, outlining feasibility, clinical applications (MRD, monitoring), and standardization needs; catalyzed rapid adoption of liquid biopsy in oncology practice and research.
  • "Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic" (2019) Systematically defined tumor mutational burden as a predictive biomarker for checkpoint inhibitors, assessing measurement methods, thresholds, and clinical implications; spurred biomarker-driven trials and informed clinical decision-making.